116 related articles for article (PubMed ID: 12224990)
1. Alefacept for psoriasis: promising drug, open questions.
Naldi L
Arch Dermatol; 2002 Sep; 138(9):1238-40. PubMed ID: 12224990
[No Abstract] [Full Text] [Related]
2. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
Ortonne JP; Khemis A; Koo JY; Choi J
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.
Gattu S; Busse K; Bhutani T; Chiang C; Nguyen T; Becker E; Koo JY
J Dermatolog Treat; 2012 Apr; 23(2):103-8. PubMed ID: 21254875
[TBL] [Abstract][Full Text] [Related]
4. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
Moul DK; Routhouska SB; Korman NJ
J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
6. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
Gribetz CH; Blum R; Brady C; Cohen S; Lebwohl M
J Am Acad Dermatol; 2005 Jul; 53(1):73-5. PubMed ID: 15965424
[TBL] [Abstract][Full Text] [Related]
7. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
[TBL] [Abstract][Full Text] [Related]
8. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
9. Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study.
Searles G; Bissonnette R; Landells I; Shear NH; Papp K; Lui H
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S131-8. PubMed ID: 20053325
[TBL] [Abstract][Full Text] [Related]
10. Efficacy outcomes in patients using alefacept in the AWARE study.
Landells I; Searles G; Bissonnette R; Shear NH; Vender R; Lui H
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S122-30. PubMed ID: 20053324
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
[TBL] [Abstract][Full Text] [Related]
12. Alefacept for the treatment of psoriasis and other dermatologic diseases.
Strober BE; Menon K
Dermatol Ther; 2007; 20(4):270-6. PubMed ID: 17970892
[TBL] [Abstract][Full Text] [Related]
13. Update on alefacept safety.
Wexler D; Searles G; Landells I; Shear NH; Bissonnette R; Papp K; Poulin Y; Langley R; Gulliver WP
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S139-47. PubMed ID: 20053326
[TBL] [Abstract][Full Text] [Related]
14. Alefacept therapy produces remission for patients with chronic plaque psoriasis.
Krueger GG; Ellis CN
Br J Dermatol; 2003 Apr; 148(4):784-8. PubMed ID: 12752139
[TBL] [Abstract][Full Text] [Related]
15. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis.
Krell J; Nelson C; Spencer L; Miller S
J Am Acad Dermatol; 2008 Apr; 58(4):609-16. PubMed ID: 18262681
[TBL] [Abstract][Full Text] [Related]
16. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients.
Haider AS; Lowes MA; Gardner H; Bandaru R; Darabi K; Chamian F; Kikuchi T; Gilleaudeau P; Whalen MS; Cardinale I; Novitskaya I; Krueger JG
J Immunol; 2007 Jun; 178(11):7442-9. PubMed ID: 17513795
[TBL] [Abstract][Full Text] [Related]
17. The AWARE study: methodology and baseline characteristics.
Bissonnette R; Searles G; Landells I; Shear NH; Papp K; Lui H; Gulliver WP; Lynde C
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S113-21. PubMed ID: 20053323
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
19. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
Scheinfeld N
J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
[TBL] [Abstract][Full Text] [Related]
20. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate.
van de Kerkhof P; Griffiths CE; Christophers E; Lebwohl M; Krueger GG
Dermatology; 2005; 211(3):256-63. PubMed ID: 16205071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
